Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database

The outcomes and best treatment strategies for germline BRCA1/2 mutation (gBRCAm) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with a gBRCAm identified at initiation of first‐line treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mailliez, Audrey, D'Hondt, Veronique, Lusque, Amelie, Caron, Olivier, Cabel, Luc, Goncalves, Anthony, Debled, Marc, Gladieff, Laurence, Ferrero, Jean‐Marc, Petit, Thierry, Mouret‐Reynier, Marie Ange, Eymard, Jean‐Christophe, Levy, Christelle, Uwer, Lionel, Leheurteur, Marianne, Desmoulins, Isabelle, Bachelot, Thomas, Frenel, Jean‐Sebastien, de la Motte Rouge, Thibault, Simon, Gaëtane, Jacot, William, Delaloge, Suzette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092337/
https://www.ncbi.nlm.nih.gov/pubmed/36161271
http://dx.doi.org/10.1002/ijc.34304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092337/
https://www.ncbi.nlm.nih.gov/pubmed/36161271
http://dx.doi.org/10.1002/ijc.34304

Ejemplares similares